Keeping score, strengthening policy, and fighting bad actors over access to research tools Read more about Keeping score, strengthening policy, and fighting bad actors over access to research tools
Ethical issues in genetic epidemiology and population genetics Read more about Ethical issues in genetic epidemiology and population genetics
Constructing narratives of heroism and villainy: A case study of Myriad’s BRACAnalysis® with Genentech’s Herceptin® Read more about Constructing narratives of heroism and villainy: A case study of Myriad’s BRACAnalysis® with Genentech’s Herceptin®
Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome. Peer-reviewed case study commissioned by the Secretary‘s Advisory Committee on Genetics, Health, and Society (SACGHS) Read more about Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome. Peer-reviewed case study commissioned by the Secretary‘s Advisory Committee on Genetics, Health, and Society (SACGHS)
You never call, you never write: Why return of “omic” results to research participants is both a good idea and a moral imperative Read more about You never call, you never write: Why return of “omic” results to research participants is both a good idea and a moral imperative
We are the genes we’ve been waiting for: Rational responses to the gathering storm of personal genomics Read more about We are the genes we’ve been waiting for: Rational responses to the gathering storm of personal genomics
Urge overkill: Protecting de-identified human subjects, but under what regime and at what price? Read more about Urge overkill: Protecting de-identified human subjects, but under what regime and at what price?
Here is a human being: At the dawn of personal genomics Read more about Here is a human being: At the dawn of personal genomics
